Rapidly progressive nephritic syndrome

N14_RAPIDPROGNEPHRITIC

No definition available.

Endpoint definition

↥

Endpoint definition steps	FinnGen
Phenotype data	520210
1. Apply sex-specific rule None	520210
2. Check conditions None	520210
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — N01# Hospital discharge: ICD-9 — 5804 Cause of death: ICD-10 — N01# Cause of death: ICD-9 — 5804 2 out of 7 registries used, show all original rules.	80
4. Check minimum number of events None	80
5. Include endpoints None	80
6. Filter based on genotype QC (FinnGen only)	80

Control definitions (FinnGen only)

Control exclude: N14_GLOMERULAR

Extra metadata

Level in the ICD hierarchy: 3
First used in FinnGen datafreeze: DF2
Parent code in ICD-10: N00-N08
Name in latin: Syndroma nephriticum cito progrediens

NAME	N14_RAPIDPROGNEPHRITIC
CONTROL_EXCLUDE	N14_GLOMERULAR
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	N01
HD_ICD_9	5804
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	N01
COD_ICD_9	5804
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Rapidly progressive nephritic syndrome based on the number of shared cases.

Similar with more cases:

Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	618	323	291
Only index persons	464	246	218
Unadjusted period prevalence (%)
Whole population	0.01	0.01	0.01
Only index persons	0.01	0.01	0.01
Median age at first event (years)
Whole population	58.72	58.87	58.31
Only index persons	52.82	52.51	53.16

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	80	40	40
Unadjusted period prevalence (%)	0.02	0.01	0.02
Median age at first event (years)	55.12	48.02	62.22

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

No data available

LabWAS

↥

(ID) Name

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(3012516) Albumin [Mass/volume] in Urine

159

6.05

14.66

9.9

3.5

300.7

55.1

mg/l

2.66

107

(3017918) Cytomegalovirus IgG Ab [Titer] in Serum or Plasma

15.21

14.64

1.5

—

(3020682) Albumin/Creatinine [Ratio] in Urine

170

5.86

14.05

12.4

4.2

58.8

7.1

mg/mmol

3.22

116

(3017766) Complement C4 [Mass/volume] in Serum or Plasma

13.92

12.96

2.0

1.4

0.3

0.2

g/l

0.74

(3000504) BK virus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection

+∞

11.74

2.8

0.0

—

(3017143) Hepatitis C virus Ab [Presence] in Serum

5.05

10.27

2.4

1.7

—

(3016431) Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma

286

5.05

10.15

38.4

8.2

1.2

mmol/l

0.15

239

(40762485) Glomerular basement membrane Ab [Units/volume] in Serum by Immunoassay

25.43

9.71

1.3

1.2

—

(3002434) Lupus erythematosus deoxynucleoproteins IgG Ab [Units/volume] in Serum by Immunoassay

8.94

9.57

2.1

1.8

—

(3010566) Parathyrin.intact [Moles/volume] in Serum or Plasma

18.49

9.44

7.6

3.6

—

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

223

4.31

9.40

17.0

2.9

—

(3012544) pH of Venous blood

5.46

9.36

15.5

4.2

—

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

104

4.23

8.52

2.3

1.8

—

(3018418) pH of Serum or Plasma

176

3.92

8.41

18.9

4.8

7.4

2.05

(3014162) Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection

8.13

8.24

4.3

2.4

—

(3023520) Reticulocytes [#/volume] in Blood

4.64

7.50

3.7

4.6

68.3

73.3

e9/l

0.28

(3040853) Adenovirus DNA [Identifier] in Specimen by NAA with probe detection

7.25

7.48

1.9

—

(3023368) Bacteria identified in Blood by Culture

180

3.62

7.47

10.0

4.3

—

(3000991) Gas panel - Venous blood

4.88

7.39

35.5

8.4

—

(3037756) Immunofixation for Serum or Plasma

7.81

7.35

1.6

1.7

—

(42870588) Differential panel, method unspecified - Blood

212

3.57

7.30

12.4

6.1

—

(3015736) pH of Urine

237

3.56

7.20

7.9

3.9

—

(3021440) Promyelocytes/100 leukocytes in Blood

4.77

7.20

7.2

5.5

0.1

0.3

—

(36304419) Bacteria [Presence] in Urine

177

3.52

7.13

12.1

2.5

—

(46235355) HIV 1 and 2 tests - Meaningful Use set

127

3.53

6.69

2.4

2.2

—

(3006504) Eosinophils/100 leukocytes in Blood

289

3.47

6.58

14.1

6.7

2.1

2.6

1.20

271

(3019069) Monocytes/100 leukocytes in Blood

290

3.45

6.53

14.2

7.1

9.4

8.6

1.07

274

(3002179) Metamyelocytes/100 leukocytes in Blood

4.55

6.51

5.0

5.6

0.2

0.4

—

(3007778) Kappa light chains/Lambda light chains [Mass Ratio] in Serum

6.24

6.51

1.8

4.8

—

(40765161) Human bocavirus DNA [Presence] in Specimen by NAA with probe detection

7.48

6.47

2.1

1.9

—

(3028026) IgM [Mass/volume] in Serum or Plasma

4.88

6.44

1.6

1.5

1.0

1.1

g/l

0.27

(3022096) Basophils/100 leukocytes in Blood

283

3.39

6.43

14.4

6.5

0.5

0.6

0.95

264

(3018559) Microscopic observation [Identifier] in Buccal smear by Cyto stain

19.99

6.42

1.3

1.0

—

(3002030) Lymphocytes/100 leukocytes in Blood

293

3.40

6.36

14.2

6.9

25.2

27.3

0.67

273

(3017181) Myelocytes/100 leukocytes in Blood

4.30

6.34

7.3

5.3

0.6

0.8

—

(3052318) Alpha-1-Microglobulin [Mass/volume] in Urine

+∞

6.32

2.2

0.0

—

(3042194) Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection

6.55

6.29

2.0

1.9

—

(3018010) Neutrophils/100 leukocytes in Blood

289

3.28

6.09

13.2

6.6

59.2

57.3

0.49

272

(3005702) Mycobacterium sp identified in Specimen by Organism specific culture

12.48

5.98

2.1

1.6

—

(3026008) Bacteria identified in Urine by Culture

195

3.10

5.81

5.4

3.6

—

(3032080) INR in Blood by Coagulation assay

243

3.10

5.80

21.6

8.7

1.1

1.2

inr

0.61

(3021879) Hepatitis B virus core Ab [Presence] in Serum

4.23

5.69

1.5

1.6

—

(3042936) Bacteria identified in Isolate by Culture

3.58

5.67

2.0

1.8

—

(3027945) Reticulocytes/100 erythrocytes in Blood

3.53

5.56

3.7

3.9

2.0

1.8

0.44

(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection

4.14

5.53

3.0

1.6

—

(3042596) Human coronavirus RNA [Presence] in Specimen by NAA with probe detection

12.47

5.44

2.2

1.1

—

(46236952) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD)

4.38

5.38

4.3

2.9

41.6

65.7

ml/min/173m2

—

(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture

3.77

5.33

6.3

4.0

—

(3004588) Protein electrophoresis panel - Serum or Plasma

4.27

5.21

1.6

3.2

—

(3042631) Mycobacterium sp identified in Specimen

11.07

5.17

4.6

4.3

—

(3048929) Epstein Barr virus Ab [Presence] in Serum

5.57

4.92

1.2

1.6

—

(3025159) Blasts/100 leukocytes in Blood

3.92

4.91

6.7

5.6

0.0

0.5

—

(3016293) Bicarbonate [Moles/volume] in Serum or Plasma

4.25

4.89

41.4

6.6

24.1

25.0

mmol/l

0.34

(3009595) Pneumocystis jiroveci DNA [Presence] in Specimen by NAA with probe detection

15.14

4.66

2.3

1.6

—

(3021601) Nitrite [Presence] in Urine by Test strip

310

2.78

4.60

15.3

5.6

0.0

estimate

0.00

(3035350) Ketones [Presence] in Urine by Test strip

311

2.77

4.56

11.3

4.1

0.0

estimate

0.00

(3037467) Urinalysis macro (dipstick) panel - Urine

423

3.07

4.39

16.3

4.5

—

(3029634) Reagin Ab [Titer] in Serum by VDRL

9.71

4.39

2.0

1.2

—

(3009261) Glucose [Presence] in Urine by Test strip

317

2.68

4.29

11.3

4.2

0.0

estimate

0.00

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

3.18

4.29

2.1

1.7

—

(3030692) Respiratory virus DNA+RNA [Identifier] in Specimen by NAA with probe detection

7.64

4.29

2.2

1.2

—

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

3.13

4.20

2.0

1.8

—

(3007844) Epstein Barr virus capsid IgM Ab [Units/volume] in Serum by Immunoassay

7.09

4.11

1.2

1.4

—

(3002482) Mycoplasma pneumoniae DNA [Presence] in Specimen by NAA with probe detection

7.09

4.11

1.8

1.6

—

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

118

2.78

4.08

2.3

1.9

—

(40760888) Immunoglobulin light chains.free panel - Serum

6.61

3.94

1.2

6.1

—

(3023150) Myeloperoxidase Ab [Units/volume] in Serum

6.61

3.94

5.0

1.1

—

(40764126) Parainfluenza virus RNA [Presence] in Specimen by NAA with probe detection

9.44

3.85

2.6

1.1

—

(3023419) Bacteria identified in Sputum by Culture

9.44

3.85

3.6

2.4

—

(3004616) Nuclear Ab [Presence] in Serum

12.81

3.82

1.7

1.0

—

(3017704) Immunofixation for Urine

12.81

3.82

1.2

1.0

—

(3022313) Gas panel - Capillary blood

3.86

3.79

20.8

3.6

—

(3036086) Jo-1 extractable nuclear Ab [Units/volume] in Serum by Immunoassay

7.26

3.77

1.6

1.2

—

(3000093) Morphology [Interpretation] in Blood Narrative

10.67

3.55

1.2

1.5

—

(3015235) Bicarbonate [Moles/volume] in Capillary blood

5.49

3.48

7.2

2.1

22.6

23.6

mmol/l

—

(1616796) Gas panel - Central venous blood

6.21

3.43

11.9

3.1

—

(3041942) Cyclic citrullinated peptide Ab [Units/volume] in Serum

2.77

3.42

1.3

1.2

53.3

9.9

u/ml

—

(3000494) Fungus identified in Specimen by Culture

2.95

3.39

1.8

1.3

—

(40762366) Oxygen capacity [Volume Fraction] in Arterial blood

3.94

3.31

42.3

10.5

—

(3049717) Cytology report of Urine Cyto stain

4.93

3.22

2.4

—

(3004119) Hemoglobin [Mass/volume] in Venous blood

3.59

3.19

9.9

4.8

112.2

124.3

g/l

1.21

(3044927) Protein electrophoresis panel - Urine

7.99

3.11

1.2

1.1

—

(3006140) Bilirubin.total [Moles/volume] in Serum or Plasma

329

2.26

3.09

9.1

6.3

9.2

11.8

umol/l

2.03

313

(3031478) Chlamydophila pneumoniae DNA [Presence] in Specimen by NAA with probe detection

6.27

3.09

2.0

1.6

—

(21493690) Lymphocyte T-cell and B-cell and Natural killer subsets panel - Blood

10.54

3.02

1.8

1.6

—

(3032699) Streptococcus pneumoniae DNA [Presence] in Specimen by NAA with probe detection

10.54

3.02

2.4

1.4

—

(3027273) Bicarbonate [Moles/volume] in Venous blood

3.67

3.02

7.5

5.2

24.5

24.4

mmol/l

—

(46237023) Hepatitis B virus core and surface Ab and surface Ag panel - Serum

5.10

3.00

1.6

1.4

—

(3027529) Toxoplasma gondii IgM Ab [Units/volume] in Serum

7.10

2.92

1.0

1.4

—

(3045424) Erythrocytes [Presence] in Urine

7.10

2.92

1.3

1.0

—

(36305247) Microscopic observation [Identifier] in Isolate by Gram stain

7.10

2.92

2.2

1.1

—

(3014959) Toxoplasma gondii IgG Ab [Units/volume] in Serum

7.10

2.92

2.0

2.9

—

(3043723) Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

4.27

2.87

2.1

3.2

—

(3021901) Oxygen saturation in Capillary blood

5.36

2.79

5.4

2.3

—

(3012477) Bordetella pertussis DNA [Presence] in Specimen by NAA with probe detection

5.36

2.79

2.0

1.6

—

(3020565) Legionella pneumophila DNA [Presence] in Specimen by NAA with probe detection

5.36

2.79

2.0

1.5

—

(3017817) Protein [Mass] in Urine collected for unspecified duration

8.78

2.79

3.2

6.7

—

(3007853) Bacteria identified in Skin by Aerobe culture

2.61

2.74

1.6

—

(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection

3.20

2.70

2.1

1.3

—

(3021614) Rheumatoid factor [Units/volume] in Serum or Plasma

2.46

2.65

1.4

1.1

40.4

37.5

iu/ml

0.05

(3029937) Albumin [Presence] in Urine by Test strip

182

2.15

2.64

11.6

4.2

0.0

estimate

—

(3032035) Polymorphonuclear cells/100 leukocytes in Blood

5.79

2.59

4.0

4.5

59.8

59.0

—

(3030905) Polymorphonuclear cells [#/volume] in Blood

5.79

2.59

3.8

4.5

4.3

4.1

e9/l

—

(3045414) Leukocytes [Presence] in Urine

4.11

2.54

2.5

1.8

—

(3027315) Oxygen [Partial pressure] in Blood

4.68

2.53

12.9

2.6

8.6

8.3

kpa

—

(3013290) Carbon dioxide [Partial pressure] in Blood

4.68

2.53

12.9

2.6

5.0

kpa

—

(3005322) IgE [Units/volume] in Serum or Plasma

3.12

2.40

1.4

1.3

94.7

141.3

u/ml

—

(40760892) CBC W Ordered Manual Differential panel - Blood

140

2.14

2.36

9.5

5.9

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

133

2.15

2.33

9.2

4.2

—

(40758558) Short blood count panel - Blood

151

2.07

2.23

10.1

8.5

—

(3015171) Extractable nuclear Ab [Units/volume] in Serum

3.93

2.20

1.3

—

(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection

2.95

2.19

2.2

1.6

—

(3052851) Hemolysis interference index of Serum or Plasma

4.54

2.19

1.8

4.2

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

284

1.91

2.11

5.6

4.6

—

(3016407) Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay

3.96

1.97

10.7

3.2

3.1

3.3

g/l

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

253

1.86

1.94

12.5

4.3

—

(3005895) Myoglobin [Mass/volume] in Serum or Plasma

3.38

1.93

3.1

2.3

10524.6

378.4

ug/l

—

(3016417) Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma

2.39

1.90

1.6

2.1

32.0

26.4

u/l

0.46

(3010517) Carboxyhemoglobin/Hemoglobin.total in Venous blood

2.95

1.85

9.6

3.1

0.9

1.3

—

(4035726)

2.44

1.84

1.8

1.4

—

(3044640) Blood type and Crossmatch panel - Blood

206

1.82

1.75

4.0

2.6

—

(40761535) Cells panel - Urine sediment

2.39

1.65

14.4

4.5

—

(3008909) Norovirus RNA [Presence] in Stool by NAA with probe detection

3.16

1.61

3.2

1.2

—

(3029379) Protein.monoclonal band 4 [Mass/volume] in Serum or Plasma by Electrophoresis

3.48

1.54

2.2

4.2

0.0

g/l

—

(3005772) Bilirubin.conjugated [Moles/volume] in Serum or Plasma

2.16

1.54

2.4

2.1

5.1

5.8

umol/l

0.17

(3024889) Methemoglobin/Hemoglobin.total in Venous blood

2.64

1.49

10.7

3.0

0.7

—

(3004529) Oxygen [Partial pressure] adjusted to patient's actual temperature in Venous blood

2.64

1.49

9.1

4.4

44.9

50.7

—

(3034780) Angiotensin converting enzyme [Enzymatic activity/volume] in Serum or Plasma

2.64

1.49

2.4

1.6

30.9

47.0

u/l

—

(3014111) Lactate [Moles/volume] in Serum or Plasma

2.34

1.47

44.6

8.1

1.1

1.2

mmol/l

—

(37019628) Gastrointestinal bacterial pathogens panel - Stool by NAA with probe detection

3.26

1.46

2.0

1.5

—

(3041096) Erythrocytes [Presence] in Urine by Automated

190

1.73

1.43

12.5

3.7

—

(3003327) Ova and parasites identified in Stool by Light microscopy

2.73

1.39

1.8

1.3

—

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

246

1.66

1.37

2.4

2.1

99.9

92.7

pmol/l

0.36

136

(3019832) Treponema pallidum Ab [Presence] in Serum

2.02

1.33

1.4

1.8

—

(3024403) Complement+Immunoglobulin [Units/volume] in Red Blood Cells

2.89

1.30

1.8

1.9

—

(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma

249

1.64

1.29

4.9

4.3

42.5

39.4

ng/l

0.07

166

(3016251) Hemoglobin.gastrointestinal [Presence] in Stool

2.41

1.21

2.8

3.0

—

(3003396) Base excess in Arterial blood by calculation

1.90

1.15

33.3

7.5

0.8

1.3

mmol/l

—

(40768443) Skin Pathology biopsy report

2.47

1.10

1.0

1.1

—

(3016879) Cocaine [Presence] in Urine

0.00

1.00

0.0

1.4

—

(3027944) Amphetamines [Presence] in Urine

0.00

0.98

0.0

1.4

—

(3028300) Cannabinoids [Presence] in Urine

0.00

0.98

0.0

1.5

—

(3027008) Opiates [Presence] in Urine

0.00

0.98

0.0

1.5

—

(3021584) Pregnancy associated plasma protein A [Units/volume] in Serum or Plasma

0.00

0.97

0.0

1.4

—

(3000764) Benzodiazepines [Presence] in Urine

0.00

0.97

0.0

1.4

—

(3013512) EKG study

181

1.55

0.96

4.4

4.7

—

(3025941) Bacteria identified in Stool by Culture

1.95

0.90

1.6

1.1

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

148

1.57

0.90

4.2

2.7

—

(40761536) Microorganisms panel - Urine sediment

1.86

0.88

14.0

3.7

—

(3019060) Gas panel - Arterial blood

1.82

0.85

6.6

4.3

—

(1001926) Buprenorphine [Presence] in Urine by Screen method

0.00

0.80

0.0

1.4

—

(3003785) Carcinoembryonic Ag [Mass/volume] in Serum or Plasma

1.66

0.69

6.9

4.4

3.4

7.3

ug/l

0.79

(40768804) Tissue Pathology biopsy report

241

1.39

0.66

2.2

1.9

—

(3002385) Erythrocyte distribution width [Ratio]

509

1.42

0.66

57.6

19.0

14.2

13.7

1.55

499

(46235759) Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection

1.71

0.62

2.4

—

(3017895) Helicobacter pylori Ab [Units/volume] in Serum

0.00

0.61

0.0

1.6

—

(3020321) Streptococcus agalactiae [Presence] in Vaginal fluid by Organism specific culture

0.00

0.61

0.0

1.6

—

(3050129) First trimester maternal screen panel - Serum or Plasma

0.00

0.60

0.0

1.2

—

(3011288) Drugs identified in Urine by Screen method

0.00

0.60

0.0

1.8

—

(40764999) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)

566

1.42

0.60

45.1

14.2

61.2

82.2

ml/min/173m2

4.87

451

(3019225) pH of Specimen

1.51

0.55

18.7

4.8

—

(3001784) Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma

169

0.72

0.42

4.1

4.3

21.0

21.7

—

(3019145) Choriogonadotropin.beta subunit free [Mass/volume] in Serum or Plasma

0.00

0.41

0.0

1.5

—

(21492888) Glucose tolerance 2 hours gestational panel - Serum or Plasma

0.00

0.41

0.0

1.6

—

(44816559) Phosphatidylethanol [Mass/volume] in Blood

0.00

0.40

0.0

1.1

—

(3008486) Thyroxine (T4) free [Moles/volume] in Serum or Plasma

449

1.24

0.35

3.1

3.8

14.1

14.8

pmol/l

1.18

405

(3005785) Creatine kinase.MB [Mass/volume] in Serum or Plasma

1.38

0.32

2.1

2.4

3.9

5.9

ug/l

—

(3000492) Spirometry study

1.32

0.31

1.1

1.3

—

(3020460) C reactive protein [Mass/volume] in Serum or Plasma

630

1.27

0.28

52.6

15.0

16.6

24.2

mg/l

2.45

511

(3002256) Pathology report gross observation

1.34

0.27

1.3

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

427

1.18

0.25

3.9

3.3

—

(40768797) Stomach Pathology biopsy report

0.73

0.25

1.0

1.3

—

(3007461) Platelets [#/volume] in Blood

694

0.79

0.25

66.5

22.3

245.3

246.0

e9/l

0.03

674

(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection

1.30

0.23

2.0

2.1

—

(3044889) 12 lead EKG panel

419

1.17

0.23

4.6

3.9

—

(3020564) Creatinine [Moles/volume] in Serum or Plasma

645

1.24

0.22

55.6

17.5

143.7

78.5

umol/l

5.57

645

(4010399)

1.20

0.22

1.2

1.3

—

(3005033) Fetal Nuchal fold Thickness US

0.00

0.21

0.0

1.4

—

(3043238) Trisomy 21 risk [Likelihood] in Fetus

0.00

0.21

0.0

1.5

—

(3047352) Trisomy 18 risk [Likelihood] in Fetus

0.00

0.21

0.0

1.4

—

(40768800) Prostate Pathology biopsy report

0.00

0.21

0.0

1.1

—

(3038177) Helicobacter pylori Ab [Presence] in Serum

0.00

0.21

0.0

1.3

—

(4094501)

0.00

0.21

0.0

1.2

—

(1002102) Choriogonadotropin.intact+Beta subunit [Mass/volume] in Serum or Plasma

0.00

0.21

0.0

1.5

—

(3039443) Prostate specific Ag panel - Serum or Plasma

0.00

0.21

0.0

1.5

—

(3028707) Methadone [Presence] in Urine by Screen method

0.00

0.21

0.0

1.6

—

(40763531) Fetal Nuchal fold [Multiple of the median] Thickness adjusted for maternal weight

0.00

0.20

0.0

1.4

—

(3008714) Choriogonadotropin [Multiple of the median] adjusted in Serum or Plasma

0.00

0.20

0.0

1.4

—

(3049207) Fetal Trisomy 21 risk [Likelihood] Based on maternal age

0.00

0.20

0.0

1.4

—

(46235831) Pregnancy associated plasma protein A [Multiple of the median] adjusted in Serum or Plasma

0.00

0.20

0.0

1.4

—

(21494755) Public health laboratory ask at order entry panel

0.74

0.17

1.0

1.3

—

(1761868) Lipid panel - Serum or Plasma

230

0.88

0.14

2.9

—

(3000963) Hemoglobin [Mass/volume] in Blood

695

0.86

0.12

65.6

22.4

125.5

134.5

g/l

4.01

681

(3010813) Leukocytes [#/volume] in Blood

695

0.86

0.12

65.5

22.3

7.0

6.9

e9/l

0.26

671

(3009542) Hematocrit [Volume Fraction] of Blood

563

1.11

0.10

46.7

15.8

38.2

39.7

0.89

405

(3024731) MCV [Entitic volume]

694

0.87

0.10

65.2

22.2

91.5

91.0

0.38

683

(3035941) MCH [Entitic mass]

694

0.87

0.10

65.1

22.2

30.3

0.08

683

(3026361) Erythrocytes [#/volume] in Blood

694

0.87

0.10

65.4

22.3

4.2

4.5

e12/l

3.02

670

(40761511) CBC panel - Blood by Automated count

644

0.90

0.09

48.8

14.4

—

(3003694) ABO and Rh group [Type] in Blood

166

1.11

0.08

1.4

1.5

—

(3019050) Tissue transglutaminase IgA Ab [Units/volume] in Serum

143

0.89

0.08

1.2

0.8

1.4

u/ml

—

(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection

1.07

0.07

2.1

2.2

—

(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep

1.09

0.02

1.4

—

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

112

0.98

0.00

1.6

—

(3006923) Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma

661

0.99

0.00

27.7

10.5

23.0

25.5

u/l

0.71

632

(3025547) Thyroglobulin Ab [Units/volume] in Serum or Plasma

0.00

0.0

2.4

—

(3014271) Vancomycin [Susceptibility]

0.00

0.0

1.8

—

(3044242) Glucose [Moles/volume] in Arterial blood

0.00

0.0

1.9

—

(3025130) Human papilloma virus identified in Specimen

0.00

0.0

1.6

—

(3016914) Bacteria identified in Cerebral spinal fluid by Culture

0.00

0.0

1.2

—

(3008832) Norclozapine [Moles/volume] in Serum or Plasma

0.00

0.0

13.4

—

1243.8

—

(3042206) Streptococcus agalactiae Ag [Presence] in Vaginal fluid

0.00

0.0

1.0

—

(3049506) Microalbumin [Mass/time] in Urine collected for unspecified duration

0.00

0.0

2.5

—

(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma

1.02

0.00

16.6

8.1

—

(3016616) Dehydroepiandrosterone sulfate (DHEA-S) [Moles/volume] in Serum or Plasma

0.00

0.0

1.0

—

7.3

—

(3017569) Oxygen content in Arterial blood

0.00

0.0

1.9

—

(3003265) Liver kidney microsomal Ab [Titer] in Serum by Immunofluorescence

0.00

0.0

1.5

—

(3020717) Zinc [Moles/volume] in Serum or Plasma

0.00

0.0

1.7

—

23.4

—

(3027953) Aldolase [Enzymatic activity/volume] in Serum or Plasma

0.00

0.0

1.2

—

4.8

—

(3013327) Hepatitis A virus IgM Ab [Presence] in Serum

0.00

0.0

1.0

—

(3046896) Herpes virus 6 DNA [Presence] in Cerebral spinal fluid by NAA with probe detection

0.00

0.0

1.2

—

(3034603) RHD gene allele [Genotype] in Blood or Tissue by Molecular genetics method Nominal

0.00

0.0

1.4

—

(3032155) Metanephrine Free [Moles/volume] in Serum or Plasma

0.00

0.0

1.3

—

(3045066) Thymidine kinase [Enzymatic activity/volume] in Serum

0.00

0.0

1.4

—

9.0

—

(3002148) Methylenedioxymethamphetamine [Presence] in Urine by Screen method

0.00

0.0

1.4

—

(3047007) Chlamydophila sp Ab [Presence] in Serum

0.00

0.0

1.3

—

(3030408) 3-Methoxytyramine [Moles/volume] in Serum or Plasma

0.00

0.0

1.3

—

(3014791) Apolipoprotein B [Mass/volume] in Serum or Plasma

0.00

0.0

2.0

—

0.8

—

(3000081) cloZAPine [Moles/volume] in Serum or Plasma

0.00

0.0

14.8

—

2252.0

—

(3007821) Glucose [Moles/volume] in Serum or Plasma --baseline

0.00

0.0

1.0

—

6.5

—

(3006257) Acetylcholine receptor Ab [Moles/volume] in Serum

0.00

0.0

1.4

—

(3019601) Blood group antibody investigation [Interpretation] in Plasma or RBC

0.00

0.0

3.1

—

(4211845)

0.00

0.0

1.4

—

(44816752) ERBB2 gene copy number/nucleus in Tissue by FISH

0.00

0.0

1.0

—

(3009340) Metanephrine [Moles/volume] in Serum or Plasma

0.00

0.0

1.1

—

(3000855) Microscopic observation [Identifier] in Vaginal fluid by Gram stain

0.00

0.0

1.0

—

(3022803) Oxygen [Partial pressure] adjusted to patient's actual temperature in Arterial blood

0.00

0.0

4.2

—

(3032773) Endomysium IgG Ab [Titer] in Serum

0.00

0.0

1.0

—

(3045156) Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Arterial blood

0.00

0.0

4.2

—

(3024666) Lithium, Blood [Moles/volume] in Serum or Plasma

0.00

0.0

7.3

—

0.7

—

(43054914) Glucose tolerance 2 hours panel - Serum or Plasma

0.96

0.00

1.4

1.9

—

(3022217) INR in Platelet poor plasma by Coagulation assay

0.89

0.00

50.9

25.7

—

1.1

—

(3006093) Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection

1.02

0.00

1.6

1.9

—

(36660697) Celiac disease serology panel - Serum

0.90

0.00

1.2

1.1

—

Mortality – FinRegistry

↥

Association

Association between endpoint N14_RAPIDPROGNEPHRITIC and mortality.

Females

Parameter	HR [95% CI]	p-value
N14_RAPIDPROGNEPHRITIC	2.733 [1.89, 3.96]	< 0.001
Birth year	0.994 [0.98, 1.0]	0.144

During the follow-up period (1.1.1998 — 31.12.2019), 78 out of 252 females with N14_RAPIDPROGNEPHRITIC died.

Males

Parameter	HR [95% CI]	p-value
N14_RAPIDPROGNEPHRITIC	3.037 [1.91, 4.83]	< 0.001
Birth year	0.986 [0.98, 1.0]	0.004

During the follow-up period (1.1.1998 — 31.12.2019), 98 out of 231 males with N14_RAPIDPROGNEPHRITIC died.

Mortality risk

Mortality risk for people of age

years, who have N14_RAPIDPROGNEPHRITIC.

N-year risk	Females	Males
1	0.228%	0.493%
5	1.488%	3.599%
10	3.874%	8.098%
15	7.352%	15.216%
20	12.18%	24.741%

Relationships between endpoints

↥

Index endpoint: N14_RAPIDPROGNEPHRITIC – Rapidly progressive nephritic syndrome

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Rapidly progressive nephritic syndrome

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints